<DOC>
	<DOCNO>NCT01083173</DOCNO>
	<brief_summary>This single-arm , multi-center , Post-Marketing Surveillance study Kaletra ( lopinavir/ritonavir ) conduct accordance approved Korean product label participant 2 year age old human immunodeficiency virus type 1 ( HIV-1 ) infection .</brief_summary>
	<brief_title>Surveillance Kaletra Korean Patients</brief_title>
	<detailed_description>Participants observe 48 week follow first dose Kaletra . A follow-up visit take place 1-2 week treatment initiation , subsequent visit occur discretion investigator , typically occur every 3 month . Clinical/immunological/virological/laboratory status , Kaletra-containing regimen/concomitant medication information , adverse event information obtain follow-up visit .</detailed_description>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Patients 2 year age HIV1 infection Patients prescribed Kaletra treatment per investigator 's medical judgment Patients give verbal write authorization use personal health data Patients start Kaletra treatment study agreement place Patients know hypersensitivity lopinavir , ritonavir excipients Kaletra tablet Patients treat treated drug contraindicate Kaletra Patients treat Kaletra Patients participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Postmarketing Drug Surveillance</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>Kaletra</keyword>
</DOC>